best college application essay competitive ancient egypt research paper research papers about media yesterday evening when my sister and i do our homework topics to do a research paper on homework chat
Skip to main content

CAAI - Covalent-allosteric AKT inhibitors


Kurzfassung

Inhibitors of the AKT pathway with a new mode of binding


Hintergrund

The development of new drugs in oncology has shifted from unspecific cytotoxic drugs to highly specific substances with known targets and modes of action. A prominent group of these target specific cancer drugs are the kinase inhibitors.


Lösung

The invented substances are inhibitors of the kinase AKT which is involved in several pathways regulating cell functions in cancer, e.g. survival and proliferation. The particular novelty of the invented compounds is based on their combined covalent-allosteric binding mode. These are first-in-class modulators of AKT with a novel mode of inhibition. Covalent-allosteric inhibitors show extended drug-target residence times.


Vorteile

  • AKT inhibitors with a new mode of action
  • The inhibitors bind AKT irreversibly and specifically with highest affinity

Anwendungsbereiche

AKT is a serine/threonine kinase and oncogene that has already been identified and addressed as a target in cancer therapy by several pharma companies. The invented substances are of high interest for any pharma company with an oncology pipeline and are of special advantage for those who seek to improve, broaden or supplement their kinase inhibitor portfolio.


Service

Binding specificity as well as an IC50 of 0.2 nM for the most promising compound have been determined by in vitro experiments so far. On behalf of the Technical University (TU) of Dortmund, PROvendis offers access to rights for commercial use as well as the opportunity for further co-development. In case of interest we will be pleased to inform you about the patent status.


PROvendis GmbH

Prof. Dr. Frank Entschladen
+49.208 94105-20
fe@provendis.info
www.provendis.info
Adresse
Schloßstr. 11-15
45468 Mülheim an der Ruhr



Entwicklungsstand

Präklinik


Stichworte

Akt, Kinase Inhibitor, Krebstherapie, small kinase inhibitor, cancer therapy

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsführerin)

c/o TransMIT GmbH
Kerkrader Straße 3
D-35394 Gießen